BCR and acute lymphoblastic leukemia: Due to the increased phosphorylation of AKT in SupB15 cells, the specific inhibitors against CK2 (CX4945) and mTOR (RAD001) in combination with the BCR-ABL inhibitor imatinib were used to investigate a potential combinatorial strategy to downregulate activated AKT signaling in Ph-positive B-ALL (Fig. 6E).